Trials / Terminated
TerminatedNCT02365584
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable malignant bowel obstruction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lanreotide (Autogel formulation) | Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration. |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-01-16
- Completion
- 2018-01-16
- First posted
- 2015-02-19
- Last updated
- 2019-11-22
- Results posted
- 2019-10-01
Locations
13 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02365584. Inclusion in this directory is not an endorsement.